Anti-Her2 single-chain antibody mediated DNMTs-siRNA delivery for targeted breast cancer therapy

Journal of Controlled Release

Volumn 161, Issue 3, 2012, Pages 875-883

  Dou, Shuang ^a   Yao, Yan Dan ^b   Yang, Xian Zhu ^a   Sun, Tian Meng ^a   Mao, Cheng Qiong ^a   Song, Er Wei ^b   Wang, Jun ^a  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Breast cancer therapy; DNA methyltransferases; Single chain antibody fragment; siRNA delivery

Indexed keywords

BREAST CANCER; BREAST CANCER CELLS; BREAST TUMOR; BREAST TUMOR CELLS; DNA METHYLTRANSFERASES; FUSION PROTEINS; INTRAVENOUS INJECTIONS; MURINE MODEL; POSITIVELY CHARGED; RNA INTERFERENCE; SINGLE-CHAIN ANTIBODIES; SIRNA DELIVERY; SMALL INTERFERING RNA (SIRNA); TARGETED DELIVERY; THERAPEUTIC APPLICATION; THERAPEUTIC DELIVERY; TUMOR CELLS; TUMOR GROWTH; TUMOR SUPPRESSOR GENES; TUMOR TISSUES;

ALKYLATION; ANTIBODIES; CELL PROLIFERATION; CELLS; DISEASES; DNA; ESCHERICHIA COLI; GENE EXPRESSION; ONCOLOGY; TUMORS;

RNA;

DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3B; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; PROTAMINE; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; DEMETHYLATION; DRUG DELIVERY SYSTEM; DRUG TARGETING; DRUG UPTAKE; ESCHERICHIA COLI; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA MODIFICATION METHYLASES; FEMALE; GENE SILENCING; HUMANS; IMMUNOGLOBULIN FRAGMENTS; MICE; MICE, INBRED BALB C; PROTAMINES; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84864619911     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.05.015     Document Type: Article

References (38)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J. Clin. 62 2012 10 29
2. D.J. Slamon, W. Godolphin, L.A. Jones, J.A. Holt, S.G. Wong, D.E. Keith, W.J. Levin, S.G. Stuart, J. Udove, and A. Ullrich Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 1989 707 712 (Pubitemid 19147683)
3. C. Wright, B. Angus, S. Nicholson, J.R. Sainsbury, J. Cairns, W.J. Gullick, P. Kelly, A.L. Harris, and C.H. Horne Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer Cancer Res. 49 1989 2087 2090 (Pubitemid 19106519)
4. M. Piccart, C. Lohrisch, A. Di Leo, and D. Larsimont The predictive value of HER2 in breast cancer Oncology 61 Suppl. 2 2001 73 82 (Pubitemid 33033428)
5. I. Genentech HERCEPTIN® (Trastuzumab) insert Sept 1998 Biotechnol. Law Rep. 17 1998 768 769
6. H.M. Shepard, G.D. Lewis, J.C. Sarup, B.M. Fendly, D. Maneval, J. Mordenti, I. Figari, C.E. Kotts, M.A. Palladino Jr., and A. Ullrich Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic J. Clin. Immunol. 11 1991 117 127
7. J. Baselga, D. Tripathy, J. Mendelsohn, S. Baughman, C.C. Benz, L. Dantis, N.T. Sklarin, A.D. Seidman, C.A. Hudis, J. Moore, P.P. Rosen, T. Twaddell, I.C. Henderson, and L. Norton Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer J. Clin. Oncol. 14 1996 737 744
8. E.N. Gal-Yam, Y. Saito, G. Egger, and P.A. Jones Cancer epigenetics: modifications, screening, and therapy Annu. Rev. Med. 59 2008 267 280 (Pubitemid 351287937)
9. M. Okano, S. Xie, and E. Li Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases Nat. Genet. 19 1998 219 220 (Pubitemid 28309328)
10. T. Bestor, A. Laudano, R. Mattaliano, and V. Ingram Cloning and sequencing of a cDNA encoding DNA methyltransferase of mouse cells. The carboxyl-terminal domain of the mammalian enzymes is related to bacterial restriction methyltransferases J. Mol. Biol. 203 1988 971 983
11. V. Nandakumar, M. Vaid, T.O. Tollefsbol, and S.K. Katiyar Aberrant DNA hypermethylation patterns lead to transcriptional silencing of tumor suppressor genes in UVB-exposed skin and UVB-induced skin tumors of mice Carcinogenesis 32 2011 597 604
12. P.M. Das, and R. Singal DNA methylation and cancer J. Clin. Oncol. 22 2004 4632 4642 (Pubitemid 41185132)
13. M. Witcher, and B.M. Emerson Epigenetic silencing of the p16(INK4a) tumor suppressor is associated with loss of CTCF binding and a chromatin boundary Mol. Cell 34 2009 271 284
14. J.K. Christman 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy Oncogene 21 2002 5483 5495 (Pubitemid 34983483)
15. S.B. Baylin DNA methylation and gene silencing in cancer Nat. Clin. Pract. Oncol. 2 Suppl. 1 2005 S4 S11
16. E. Kaminskas, A.T. Farrell, Y.C. Wang, R. Sridhara, and R. Pazdur FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension Oncologist 10 2005 176 182 (Pubitemid 40463154)
17. P.W. Laird The power and the promise of DNA methylation markers Nat. Rev. Cancer 3 2003 253 266 (Pubitemid 37328861)
18. R. Kole, A.R. Krainer, and S. Altman RNA therapeutics: beyond RNA interference and antisense oligonucleotides Nat. Rev. Drug Discov. 11 2012 125 140
19. C.F. Bennett, and E.E. Swayze RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform Annu. Rev. Pharmacol. 50 2010 259 293
20. Y.W. Leu, F. Rahmatpanah, H. Shi, S.H. Wei, J.C. Liu, P.S. Yan, and T.H. Huang Double RNA interference of DNMT3b and DNMT1 enhances DNA demethylation and gene reactivation Cancer Res. 63 2003 6110 6115 (Pubitemid 37255146)
21. A. de Fougerolles, H.P. Vornlocher, J. Maraganore, and J. Lieberman Interfering with disease: a progress report on siRNA-based therapeutics Nat. Rev. Drug Discov. 6 2007 443 453 (Pubitemid 47064567)
22. J.P. Issa DNA methylation as a therapeutic target in cancer Clin. Cancer Res. 13 2007 1634 1637
23. I. Rhee, K.E. Bachman, B.H. Park, K.W. Jair, R.W. Yen, K.E. Schuebel, H. Cui, A.P. Feinberg, C. Lengauer, K.W. Kinzler, S.B. Baylin, and B. Vogelstein DNMT1 and DNMT3b cooperate to silence genes in human cancer cells Nature 416 2002 552 556 (Pubitemid 34288859)
24. Y. Jung, J. Park, T.Y. Kim, J.H. Park, H.S. Jong, S.A. Im, K.D. Robertson, and Y.J. Bang Potential advantages of DNA methyltransferase 1 (DNMT1)-targeted inhibition for cancer therapy J. Mol. Med. 85 2007 1137 1148 (Pubitemid 47476731)
25. Y.K. Oh, and T.G. Park siRNA delivery systems for cancer treatment Adv. Drug Deliv. Rev. 61 2009 850 862
26. X. Li, P. Stuckert, I. Bosch, J.D. Marks, and W.A. Marasco Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells Cancer Gene Ther. 8 2001 555 565 (Pubitemid 32786558)
27. E. Song, P. Zhu, S.K. Lee, D. Chowdhury, S. Kussman, D.M. Dykxhoorn, Y. Feng, D. Palliser, D.B. Weiner, P. Shankar, W.A. Marasco, and J. Lieberman Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors Nat. Biotechnol. 23 2005 709 717 (Pubitemid 41716361)
28. W.H. Wen, J.Y. Liu, W.J. Qin, J. Zhao, T. Wang, L.T. Jia, Y.L. Meng, H. Gao, C.F. Xue, B.Q. Jin, L.B. Yao, S.Y. Chen, and A.G. Yang Targeted inhibition of HBV gene expression by single-chain antibody mediated small interfering RNA delivery Hepatology 46 2007 84 94 (Pubitemid 47171924)
29. Q. Tao, H. Huang, T.M. Geiman, C.Y. Lim, L. Fu, G.H. Qiu, and K.D. Robertson Defective de novo methylation of viral and cellular DNA sequences in ICF syndrome cells Hum. Mol. Genet. 11 2002 2091 2102 (Pubitemid 34993997)
30. Q. Tao, L.J. Swinnen, J. Yang, G. Srivastava, K.D. Robertson, and R.F. Ambinder Methylation status of the Epstein-Barr virus major latent promoter C in iatrogenic B cell lymphoproliferative disease. Application of PCR-based analysis Am. J. Pathol. 155 1999 619 625 (Pubitemid 29370411)
31. S. Kawakami, and M. Hashida Targeted delivery systems of small interfering RNA by systemic administration Drug Metab. Pharmacokinet. 22 2007 142 151
32. T.M. Sun, J.Z. Du, L.F. Yan, H.Q. Mao, and J. Wang Self-assembled biodegradable micellar nanoparticles of amphiphilic and cationic block copolymer for siRNA delivery Biomaterials 29 2008 4348 4355
33. S. Chono, S.D. Li, C.C. Conwell, and L. Huang An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor J. Control. Release 131 2008 64 69
34. R. Dammann, G. Yang, and G.P. Pfeifer Hypermethylation of the CpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers Cancer Res. 61 2001 3105 3109 (Pubitemid 32691961)
35. M. Widschwendter, and P.A. Jones DNA methylation and breast carcinogenesis Oncogene 21 2002 5462 5482 (Pubitemid 34983482)
36. S. Thaler, M. Schmidt, A. Schad, and J.P. Sleeman RASSF1A inhibits estrogen receptor alpha expression and estrogen-independent signalling: implications for breast cancer development Oncogene 2012 10.1038/onc.2011.658
37. M. Lubbert DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action Curr. Top. Microbiol. Immunol. 249 2000 135 164 (Pubitemid 30134342)
38. N. Yagi, I. Manabe, T. Tottori, A. Ishihara, F. Ogata, J.H. Kim, S. Nishimura, K. Fujiu, Y. Oishi, K. Itaka, Y. Kato, M. Yamauchi, and R. Nagai A nanoparticle system specifically designed to deliver short interfering RNA inhibits tumor growth in vivo Cancer Res. 69 2009 6531 6538